SavedAdd your journal

Journals / Meandros Medical And Dental Journal / 2023 / Volume: 24 Issue: 4

Differences in the Differential Expression of MicroRNAs Between Patients with Familial Multiple Sclerosis and Those with Sporadic Multiple Sclerosis

Halil Güllüoğlu(IZMIR UNIVERSITY OF ECONOMICS)
Hasan Armağan Uysal(IZMIR UNIVERSITY OF ECONOMICS)
Turan Poyraz(IZMIR UNIVERSITY OF ECONOMICS)
Zekiye Altun(DOKUZ EYLUL UNIVERSITY)
Derya Kaya(DOKUZ EYLUL UNIVERSITY)
Pınar Özçelik(BEZMI ALEM FOUNDATION UNIVERSITY)
Egemen İdiman(DOKUZ EYLUL UNIVERSITY)
Pages
—
Publication Date
2023-12-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study showedthat miRNAs may discriminate between FMS and sMS cases and MS subtypes, as indicated in earlier studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Multiple sclerosis (MS) is a heterogeneous disease with clinical and immunological features.
📊
Key Findings & Data:Materials and Methods: This cross-section, single-center study was conducted in 20 FMS and 10 sMS patients and 8 healthycontrols.
💡
Conclusion & Impact:This study showedthat miRNAs may discriminate between FMS and sMS cases and MS subtypes, as indicated in earlier studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Multiple sclerosis · familial MS · sporadic MS

Abstract

Objective: Multiple sclerosis (MS) is a heterogeneous disease with clinical and immunological features. Most MS cases occursporadically, but a considerable proportion of patients have a family history of MS. The etiology and pathophysiology of MSremainunclear. Recent epidemiological and gene expression studies have indicated that dysregulation of microRNAs (miRNAs) may playarole in MS pathogenesis. This study aimed to evaluate the differential expression of miRNAs in sporadic MS (sMS) and familial MS(FMS) patients. Materials and Methods: This cross-section, single-center study was conducted in 20 FMS and 10 sMS patients and 8 healthycontrols. The patients were in the remission. In total, 2,549 miRNA genes were screened in the blood mononuclear cells fromthewhole blood samples of MS patients depending on miRBase 21. Differential expression of miRNAs in MS patients was identifiedcompared with the control group, and miRNAs with a fold change ≥2 were validated using reverse transcription-polymerase chainreaction. Differentially expressed miRNAs were then compared between FMS and sMS patients. Results: Initial findings showed that miR-5100 and hsa-miR-16-2-3p were increased and miR-432-3p was decreased inFMScompared with sMS, whereas miR-548-aa, hsa-miR-142-3p, and miR-451-b were increased in both sMS and FMS, but miR-548-vwas increased only in sMS. Some miRNAs showed the same expression patterns in both groups. Conclusion: Differential expression of certain miRNAs may be a useful biomarker in the diagnosis of MS. This study showedthat miRNAs may discriminate between FMS and sMS cases and MS subtypes, as indicated in earlier studies.

🔖

Cite This Article

Güllüoğlu, H., Uysal, H. A., Poyraz, T., Altun, Z., Kaya, D., Özçelik, P., İdiman, E. (2023). Differences in the Differential Expression of MicroRNAs Between Patients with Familial Multiple Sclerosis and Those with Sporadic Multiple Sclerosis. Meandros Medical And Dental Journal, Volume: 24 Issue: 4. https://doi.org/10.4274/meandros.galenos.2023.71135

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31.
  2. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-86.
  3. Harirchian MH, Fatehi F, Sarraf P, Honarvar NM, Bitarafan S. Worldwide prevalence of familial multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord 2018; 20: 43-7.
  4. Muñoz-Culla M, Irizar H, Otaegui D. The genetics of multiple sclerosis: review of current and emerging candidates. Appl Clin Genet 2013; 6: 63-73.
  5. Mansoor SR, Ghasemi-Kasman M, Yavarpour-Bali H. The role of microRNAs in multiple sclerosis. Int Rev Immunol 2022; 41: 57-71.
  6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
  7. Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS, et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 2013; 73: 729-40.
  8. Otaegui D, Baranzini SE, Armañanzas R, Calvo B, Muñoz-Culla M, Khankhanian P, et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 2009; 4: e6309.
  9. Gao Y, Han D, Feng J. MicroRNA in multiple sclerosis. Clin Chim Acta 2021; 516: 92-9.
  10. Nuzziello N, Vilardo L, Pelucchi P, Consiglio A, Liuni S, Trojano M, et al. Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis. Int J Mol Sci 2018; 19: 3652.
  11. Abolghasemi M, Ashrafi SA, Asadi M, Shanehbandi D, Etehad SS, Poursaei E, et al. Altered miR-10, miR-24a, miR-124, and miR-21 expression in peripheral blood mononuclear cells of patients with multiple sclerosis. Preprint. Available from: https://assets. researchsquare.com/files/rs-1490169/v1/ea525601-112a-4281- 982e-c97463c22b37.pdf?c=1648750902.
  12. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-8.
  13. Piket E, Zheleznyakova GY, Kular L, Jagodic M. Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: A comprehensive overview. J Autoimmun 2019; 101: 17-25.
  14. Muñoz-San Martín M, Gómez I, Quiroga-Varela A, Gonzalez-Del Río M, Robles Cedeño R, Álvarez G, et al. miRNA Signature inCSFFrom Patients With Primary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm 2022; 10: e200069.
  15. Keller A, Leidinger P, Steinmeyer F, Stähler C, Franke A, HemmrichStanisak G, et al. Comprehensive analysis of microRNAprofilesinmultiple sclerosis including next-generation sequencing. Mult Scler2014; 20: 295-303.
  16. Wei Z, Lyu B, Hou D, Liu X. Mir-5100 Mediates Proliferation, Migration and Invasion of Oral Squamous Cell Carcinoma CellsViaTargeting SCAI. J Invest Surg 2021; 34: 834-41.
  17. Zhang HM, Li H, Wang GX, Wang J, Xiang Y, Huang Y, et al. MKL1/miR-5100/CAAP1 loop regulates autophagy and apoptosis in gastriccancer cells. Neoplasia 2020; 22: 220-30.
  18. Yang D, Wang WZ, Zhang XM, Yue H, Li B, Lin L, et al. MicroRNAexpression aberration in Chinese patients with relapsing remittingmultiple sclerosis. J Mol Neurosci 2014; 52: 131-7.
  19. Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, et al. Multiple sclerosis: microRNA expression profiles accuratelydifferentiate patients with relapsing-remitting disease fromhealthycontrols. PLoS One 2009; 4: e7440.
  20. McCoy CE. miR-155 Dysregulation and Therapeutic InterventioninMultiple Sclerosis. Adv Exp Med Biol 2017; 1024: 111-31.
  21. Ma X, Zhou J, Zhong Y, Jiang L, Mu P, Li Y, et al. Expression, regulation and function of microRNAs in multiple sclerosis. Int JMed Sci 2014; 11: 810-8.
  22. Mandolesi G, Rizzo FR, Balletta S, Stampanoni Bassi M, GilioL, Guadalupi L, et al. The microRNA let-7b-5p Is Negatively Associatedwith Inflammation and Disease Severity in Multiple Sclerosis. Cells2021; 10: 330.
  23. Søndergaard HB, Hesse D, Krakauer M, Sørensen PS, SellebjergF. Differential microRNA expression in blood in multiple sclerosis. Mult Scler 2013; 19: 1849-57.
  24. Cox MB, Cairns MJ, Gandhi KS, Carroll AP, Moscovis S, Stewart GJ, et al. MicroRNAs miR-17 and miR-20a inhibit T cell activationgenesand are under-expressed in MS whole blood. PLoS One 2010; 5: e12132.
  25. Ebrahimkhani S, Vafaee F, Young PE, Hur SSJ, Hawke S, DevenneyE, et al. Exosomal microRNA signatures in multiple sclerosis reflect disease status. Sci Rep 2017; 7: 14293.